Fluxome launches beta glucan for immune support

EFSA turns down beta-glucan immunity health claim

28-May-2010

The latest negative health claim opinion from the European Food Safety Authority (EFSA) finds no immune benefits linked to a yeast extract supplied by German firm Leiber.

Nutraceutical partnership targets US beta glucan market

16-Mar-2010

Two Scandanavian companies have teamed up to supply a beta glucan product to US consumers who spend an estimated $80-100m each year on this market segment.

Fluxome prepares yeast-fermented resveratrol for US market

03-Nov-2008

Danish biotech firm Fluxome is preparing to launch a yeast-fermented resveratrol in the US market, which it claims will deliver a consistent high quality and purity ingredient at a commercially viable price.

Fluxome launches beta glucan for immune support

Fluxome is launching a new beta-glucan ingredient onto the US market, where it is targeting dietary supplement applications for immune health.

Related Topics

EFSA turns down beta-glucan immunity health claim

Nutraceutical partnership targets US beta glucan market

Fluxome prepares yeast-fermented resveratrol for US market